Hepatoma derived growth factor and vascular smooth muscle cell proliferation
肝癌源性生长因子与血管平滑肌细胞增殖
基本信息
- 批准号:7903929
- 负责人:
- 金额:$ 36.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-04-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcetylationAddressAlanineAmino AcidsAntibodiesArterial Fatty StreakArteriesBindingBinding ProteinsBiological AssayBlood VesselsBrainCardiovascular DiseasesCause of DeathCell CycleCell NucleusCellsCholesterolCollaborationsD-Aspartic AcidDNA BindingDNA-Binding ProteinsDataDevelopmentEMSAFutureGene TargetingGenetic TranscriptionGoalsGrowthGrowth FactorHeartHistone DeacetylaseHistone deacetylase inhibitionHistonesHumanImmune SeraIn VitroInjuryInterventionKnockout MiceLaboratoriesLinkMediatingModelingMusMutationNuclearPKC Phosphorylation SitePWWP DomainPathway interactionsPatientsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPilot ProjectsPositioning AttributePost-Translational RegulationProcessProductionProliferatingProtein Kinase CProteinsPublic HealthReagentRecombinant AntibodyRelative (related person)Research PersonnelRoleSerineSerumSignal TransductionSmooth Muscle MyocytesStentsStructureTestingTranscription Repressor/CorepressorUnited StatesVascular Diseasesbasecell growthdesigngene repressionhepatoma-derived growth factorin vivoinjuredmutantnovel therapeuticsprogramspromoterprotein functionresearch studyresponseresponse to injuryvascular smooth muscle cell proliferation
项目摘要
DESCRIPTION (provided by applicant): Smooth muscle cell (VSMC) proliferation is a key component of the pathophysiologic response to vascular injury. Central to this process is the production and activation of growth factors. One such VSMC growth factor, hepatoma derived growth factor (HDGF), becomes highly expressed in the nucleus of neointimal cells after balloon injury and is co-expressed with PCNA in proliferating VSMC in human atherosclerotic plaques. However, the mechanisms by which HDGF stimulates VSMC proliferation are unknown. The overall goal of this proposal is to elucidate the nuclear mechanisms by which HDGF stimulates VSMC proliferation in vitro and in response to injury. In our pilot studies, we found that HDGF is phosphorylated by protein kinase C, a key signaling intermediate in vascular injury. We also now have evidence that HDGF is a nuclear binding protein, functioning as a transcriptional repressor. Based upon these studies, we propose to determine the mechanisms of PKC mediated post-translational regulation of HDGF mitogenic function in vitro and in vivo and as a DMA binding, transcriptional repressor. First, we will test the hypothesis that PKC phosphorylation s critical to HDGF mitogenic function in isolated VSMC and in the wire injured mouse carotid using adenoviral expression of single or combination mutations of candidate PKC serines (S) to alanine (A, loss of phosphorylation) or aspartic acid (D, phosphorylation mimic) mutations, PKCa deficient knockout mice, and phospho-specific HDGF antibodies. Second, we will test the hypotheses that HDGF is a DNA binding protein using NMR based structure/function analyses, functions as a transcriptional repressor binding to the promoters of HDGF target genes via the controversial PWWP domain, whether transcriptional repression is mediated by the HDAC pathway and whether these activities are regulated by PKC phosphorylation. The significance of the proposed studies is that by linking HDGF activation with PKC, a critical step in the function of HDGF in vascular injury is revealed and provides the basis for new therapeutic strategies in vascular disease. Relevance to public health: Cardiovascular disease is the number one cause of death in the United States despite interventions with cholesterol lowering agents and the development of endovascular stents. This is because of the continued detrimental growth of vascular cells in the damaged arteries of patients; eventually, leading to vascular insufficiency of the brain or heart. We have identified a protein (HDGF) produced by vascular cells in diseased arteries that increases the growth of vascular cells. We propose here to determine the mechanism regulating the activity of this protein to provide the basis for the future design of new drugs to treat cardiovascular disease.
描述(申请人提供):血管平滑肌细胞(VSMC)增殖是血管损伤病理生理反应的关键组成部分。这一过程的核心是生长因子的产生和激活。其中一种VSMC生长因子--肝癌衍生生长因子(HDGF)在球囊损伤后高表达于新生内膜细胞的胞核,并在人动脉粥样硬化斑块中与增殖的VSMC共表达。然而,HDGF刺激VSMC增殖的机制尚不清楚。这项建议的总体目标是阐明HDGF在体外刺激VSMC增殖和对损伤做出反应的核机制。在我们的初步研究中,我们发现HDGF被蛋白激酶C磷酸化,蛋白激酶C是血管损伤的关键信号中间体。我们现在也有证据表明,HDGF是一种核结合蛋白,起着转录抑制因子的作用。在这些研究的基础上,我们建议确定PKC在体外和体内对HDGF有丝分裂功能的翻译后调节机制以及作为DMA结合、转录抑制因子的机制。首先,我们将通过腺病毒表达候选PKC丝氨酸(S)到丙氨酸(A)或天冬氨酸(D)突变的单个或组合突变、PKCA缺陷敲除小鼠和磷酸化特异的HDGF抗体来验证PKC磷酸化对高密度脂蛋白生长因子有丝分裂功能至关重要的假说。其次,我们将通过基于核磁共振的结构/功能分析来验证以下假设:HDGF是一个DNA结合蛋白,作为转录抑制因子通过有争议的PWWP结构域与HDGF靶基因的启动子结合,转录抑制是否通过HDAC途径介导,这些活性是否受PKC磷酸化的调节。这项研究的意义在于,通过将HDGF的激活与PKC联系起来,揭示了HDGF在血管损伤中作用的关键步骤,并为血管疾病的新治疗策略提供了基础。与公共健康相关:心血管疾病是美国头号死亡原因,尽管有降胆固醇药物的干预和血管内支架的开发。这是因为患者受损动脉中的血管细胞持续有害生长,最终导致脑血管或心脏血管功能不全。我们已经确定了一种由病变动脉中的血管细胞产生的蛋白质(HDGF),它可以促进血管细胞的生长。我们建议确定该蛋白活性的调节机制,为将来设计治疗心血管疾病的新药提供依据。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hepatoma-derived growth factor binds DNA through the N-terminal PWWP domain.
肝癌衍生的生长因子通过N末端pwwp结构域结合DNA。
- DOI:10.1186/1471-2199-8-101
- 发表时间:2007-10-31
- 期刊:
- 影响因子:0
- 作者:Yang, Jun;Everett, Allen D.
- 通讯作者:Everett, Allen D.
Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein.
- DOI:10.1016/j.jmb.2008.12.080
- 发表时间:2009-03-06
- 期刊:
- 影响因子:5.6
- 作者:Yang, Jun;Everett, Allen D.
- 通讯作者:Everett, Allen D.
Development of the MAGIC congenital heart disease catheterization database for interventional outcome studies.
- DOI:10.1111/j.1540-8183.2006.00128.x
- 发表时间:2006-04-01
- 期刊:
- 影响因子:2.1
- 作者:Everett, Allen D;Ringel, Richard;Lim, D Scott
- 通讯作者:Lim, D Scott
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALLEN D EVERETT其他文献
COMPARISON BETWEEN PULMONARY ARTERIAL HYPERTENSION (PAH) RISK ASSESSMENT METHODS, INCLUDING PULMONARY HYPERTENSION OUTCOME RISKS ASSESSMENT (PHORA)
- DOI:
10.1016/j.chest.2022.08.2013 - 发表时间:
2022-10-01 - 期刊:
- 影响因子:
- 作者:
CHARLES FAUVEL;ZILU LIU;SHILI LIN;PRISCILLA CORREA-JAQUE;AMY WEBB;REBECCA R VANDERPOOL;MANREET KANWAR;JIDAPA KRAISANGKA;PUNEET MATHUR;ADAM PERER;ALLEN D EVERETT;RAYMOND L BENZA - 通讯作者:
RAYMOND L BENZA
ALLEN D EVERETT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALLEN D EVERETT', 18)}}的其他基金
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes
环己酮毒性在调节先天性心脏手术结果中的作用
- 批准号:
10627951 - 财政年份:2022
- 资助金额:
$ 36.9万 - 项目类别:
Role of Cyclohexanone Toxicity in Mediating Congenital Cardiac Surgery Outcomes
环己酮毒性在调节先天性心脏手术结果中的作用
- 批准号:
10444513 - 财政年份:2022
- 资助金额:
$ 36.9万 - 项目类别:
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE
新生儿 HIE 的先进低温治疗功效网络模型
- 批准号:
10696194 - 财政年份:2022
- 资助金额:
$ 36.9万 - 项目类别:
Advanced therapeutic hypothermia efficacy network modeling in neonatal HIE
新生儿 HIE 的先进低温治疗功效网络模型
- 批准号:
10538972 - 财政年份:2022
- 资助金额:
$ 36.9万 - 项目类别:
Clinical and mechanistic role of HDGF in pulmonary hypertension
HDGF 在肺动脉高压中的临床和机制作用
- 批准号:
9772631 - 财政年份:2017
- 资助金额:
$ 36.9万 - 项目类别:
Adult Biomarkers in Neonatal Brain Injury and Development
新生儿脑损伤和发育中的成人生物标志物
- 批准号:
9761549 - 财政年份:2016
- 资助金额:
$ 36.9万 - 项目类别:
Adult Biomarkers in Neonatal Brain Injury and Development
新生儿脑损伤和发育中的成人生物标志物
- 批准号:
9549109 - 财政年份:2016
- 资助金额:
$ 36.9万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 36.9万 - 项目类别:
Research Grant